DRIO trades 80.6% below Wall Street's consensus target of $12.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes DRIO achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, DarioHealth Corp. (DRIO) has a Wall Street consensus price target of $12.50, based on estimates from 9 covering analysts. With the stock currently trading at $6.92, this represents a potential upside of +80.6%. The company has a market capitalization of $343M.
Analyst price targets range from a low of $7.50 to a high of $16.00, representing a 68% spread in expectations. The median target of $14.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, DRIO trades at a trailing P/E of 5.6x. Analysts expect EPS to grow -393.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
TDOCTeladoc Health, Inc. | $1.5B | $8.39 | $7.40 | -11.8% | Hold | — | 42 |
OMCLOmnicell, Inc. | $1.8B | $40.13 | $57.20 | +42.5% | Hold | 20.7x | 19 |
NVCRNovoCure Limited | $1.8B | $15.43 | $33.00 | +113.9% | Buy | — | 15 |
HIMSHims & Hers Health, Inc. | $7.5B | $33.94 | $28.08 | -17.3% | Hold | — | 20 |
DXCMDexCom, Inc. | $27.1B | $70.14 | $83.80 | +19.5% | Buy | 27.1x | 52 |
ABTAbbott Laboratories | $163.4B | $93.82 | $126.00 | +34.3% | Buy | 17.1x | 41 |
PODDInsulet Corporation | $11.1B | $158.25 | $220.79 | +39.5% | Buy | 24.4x | 50 |
TNDMTandem Diabetes Care, Inc. | $1.1B | $16.24 | $29.95 | +84.4% | Buy | — | 39 |
GDRXGoodRx Holdings, Inc. | $971M | $2.80 | $3.08 | +10.0% | Hold | 9.1x | 24 |
CVSCVS Health Corporation | $133.1B | $104.34 | $103.64 | -0.7% | Buy | 14.1x | 41 |
Quick answers to the most common questions about buying DRIO stock.
The consensus Wall Street price target for DRIO is $12.5, representing 80.6% upside from the current price of $6.92. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
DRIO has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $12.5 implies 80.6% upside from current levels.
DRIO's current price is $6.92 with a consensus target of $12.5 (80.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $16 for DRIO, while the most conservative target is $7.5. The consensus of $12.5 represents the median expectation. These targets typically reflect 12-month expectations.
DRIO is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month DRIO stock forecast based on 9 Wall Street analysts shows a consensus price target of $12.5, with estimates ranging from $7.5 (bear case) to $16 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on DRIO, with a "Buy" consensus rating and $12.5 price target (80.6% upside). 8 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
DRIO analyst price targets range from $7.5 to $16, a 68% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $12.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.